EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance

David Wilson iD, Sateesh Jayappa, Lora Parker, Eylem Ocal iD, Tomoko Tanaka, Murat Gokden, Kevin Bielamowicz

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26209864 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von David Wilson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72223, USA. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Brain Neoplasms, Drug Resistance, Neoplasm, Glioma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric-type diffuse high-grade gliomas (pHGGs) tend to have a dismal prognosis. Some of these gliomas feature alterations in genes such as ROS1, ALK, MET, and NTRK1–3. Despite development of targeted agents, the therapeutic application of these agents in pHGGs is still unclear. The aim of this retrospective case series is to report the outcome of two patients with pHGGs who were treated at Arkansas Children’s Hospital with targeted agents (Cabozantinib for a MET fusion in patient 1 and Lorlatinib for an ALK fusion in patient 2) with an initial, objective response followed by treatment resistance. Each diagnosis was determined based on histology, targeted tumor sequencing, and methylation profiling. In both cases, relapse occurred while on targeted inhibition. Recurrent tumor sequencing for patient 2 revealed a MET copy gain suggesting a mechanism of resistance in this patient. Pediatric high-grade gliomas with targetable alterations can show objective responses to pathway inhibition. Relapse after initial response may warrant additional surgical samples to identify new alterations which can lead to changes in therapy. Larger prospective cohorts are needed to study targeted agents in this population, and earlier integration of these agents may be beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anaplastic Lymphoma KinaseBrain NeoplasmsDrug Resistance, NeoplasmGliomaProtein Kinase InhibitorsProto-Oncogene Proteins c-metChild, PreschoolFemaleHumansMaleAminopyridinesLactams, MacrocyclicMolecular Targeted TherapyInfantLactamsPyrazoles

Stichwörter der Autor:innen

ALK alterationMET alterationbrain tumorgliomapediatric CNS tumorpediatric high-grade glioma

Substanzen

ALK protein, humanAminopyridinesAnaplastic Lymphoma KinaseLactams, MacrocycliclorlatinibMET protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-metLactamsPyrazoles

Autor:innen und Institutionen

  • Department of Pediatrics, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72223, USA.
  • Section of Pediatric Hematology/Oncology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72223, USA.
  • Arkansas Children's Hospital (ACH), Little Rock, AR 72223, USA.
  • Department of Radiology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72223, USA.
  • Department of Neurosurgery, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72223, USA.
  • Department of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72223, USA.

ORCID-Profile: David Wilson, Eylem Ocal

Zitieren

APA

Wilson, D., Jayappa, S., Parker, L., Ocal, E., Tanaka, T., Gokden, M., & Bielamowicz, K. (2025). Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26209864

Vancouver

Wilson D, Jayappa S, Parker L, Ocal E, Tanaka T, Gokden M, et al. Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26209864

BibTeX
@article{Wilson2025,
  author = {Wilson, David and Jayappa, Sateesh and Parker, Lora and Ocal, Eylem and Tanaka, Tomoko and Gokden, Murat and Bielamowicz, Kevin},
  title = {Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26209864}
}
Kostenlos starten →